Seizures Risk Related to Atypical Antipsychotics: A Disproportionality Analysis Based on the FDA Adverse Event Reporting System (FAERS)

Background: This pharmacovigilance study aimed to characterize the spectrum of seizure-related adverse events (AEs) associated with eight commonly used atypical antipsychotics (AAPs)-clozapine, quetiapine, olanzapine, aripiprazole, ziprasidone, risperidone, lurasidone, and paliperidone-based on the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database, and to explore potential receptor mechanisms underlying AAP-related seizures. Methods: /D2 receptor ratios. Results: = 0.036). Conclusions: /D2 ratio suggests a potential pharmacodynamic mechanism. Clinicians should consider these differential risks, especially when prescribing for patients with predisposing factors, and maintain vigilance for specific seizures types. These findings warrant further validation through prospective studies and clinical causality assessments.